ENGN

Engene Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↑ 5/10
  • Value↓ 4/10
Engene Therapeutics sales and earnings growth
ENGN Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -48.03%
  • FCF Y/Y↓ -54.16%
Engene Therapeutics gross and profit margin trends
ENGN Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Engene Therapeutics net debt vs free cash flow
ENGN Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -40.2

Engene Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks